TrialPath
← Back to searchRecruiting

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

NCT03821857 · Mayo Clinic
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
The proposed project will enroll a total of 614 women. Mayo Clinic Rochester Participants: Each women will have 2-3 clinic visits consisting of cognitive testing, tests of physical function, questionnaires, and a blood draw. All women will also undergo clinical neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451. All participants will have previously participated and will return by invitation only. Mayo Clinic Jacksonville Participant: Only African American Women will be enrolled at this site. Each women will have 1-3 clinic visits consisting of physical function testing and neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451.
Eligibility criteria
Mayo Clinic Rochester- Inclusion Criteria: * Women who previously participated in this study * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent Exclusion Criteria: * Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation Mayo Clinic Jacksonville- Inclusion Criteria: * African American Women * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent Exclusion Criteria: * Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation
Study design
Enrollment target: 614 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2019-06-27
Estimated completion: 2030-05
Last updated: 2025-11-24
Interventions
Drug: 18-F-Flortaucipir
Primary outcomes
  • 18F-Flortaucipir PET imaging (1 day)
  • Pittsburgh compound-B PET imaging (1 day)
Sponsor
Mayo Clinic · other
With: National Institute on Aging (NIA)
Contacts & investigators
ContactJune Kendall-Thomas, CRC · contact · kendallthomas.june15@mayo.edu · 507-293-9397
ContactDesirae Howe-Clayton, CRC · contact · howe.desirae@mayo.edu · 507-255-0111
InvestigatorKejal Kantarci, MD · principal_investigator, Mayo Clinic
All locations (2)
Mayo ClinicRecruiting
Jacksonville, Florida, United States
Mayo ClinicEnrolling By Invitation
Rochester, Minnesota, United States
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease · TrialPath